PTLF (Petlife Pharmaceuticals) Total Equity: $-1.97 Mil (As of Feb. 2018)


What is Petlife Pharmaceuticals Total Equity?

Petlife Pharmaceuticals PTLF Total Equity is $-1.97 Mil as of Feb. 2018.

Petlife Pharmaceuticals's total equity for the quarter that ended in Feb. 2018 was $-1.97 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Petlife Pharmaceuticals Total Equity Historical Data

* Premium members only.

The historical data trend for Petlife Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Petlife Pharmaceuticals Total Equity Chart

Petlife Pharmaceuticals Annual Data
Trend Aug08 Aug09 Aug10 Aug11 Aug12 Aug13 Aug14 Aug15 Aug16 Aug17
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.02 -0.37 -3.24 -1.38

Petlife Pharmaceuticals Quarterly Data
May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.91 -1.32 -1.38 -1.77 -1.97

Petlife Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Petlife Pharmaceuticals's Total Equity for the fiscal year that ended in Aug. 2017 is calculated as

Total Equity=Total Assets(Q: Aug. 2017 )-Total Liabilities(Q: Aug. 2017 )
=0.055-1.436
=-1.38

Petlife Pharmaceuticals's Total Equity for the quarter that ended in Feb. 2018 is calculated as

Total Equity=Total Assets(Q: Feb. 2018 )-Total Liabilities(Q: Feb. 2018 )
=0.008-1.981
=-1.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $-1.97 Mil mean?
Petlife Pharmaceuticals (PTLF) has a Total Equity of $-1.97 Mil as of Feb. 2018. The total amount of equity as record on a company's balance sheet. View historical data for Petlife Pharmaceuticals and its competitors.
Is Petlife Pharmaceuticals' Total Equity too high?
Petlife Pharmaceuticals' current Total Equity is $-1.97 Mil.
How does Petlife Pharmaceuticals' Total Equity compare to PCYN and YBAO?
Petlife Pharmaceuticals' Total Equity of $-1.97 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Petlife Pharmaceuticals and its competitors. Petlife Pharmaceuticals's current Total Equity is $-1.97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petlife Pharmaceuticals stock overvalued right now?
Petlife Pharmaceuticals (PTLF) has a current Total Equity of $-1.97 Mil. The current Total Equity is $-1.97 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Petlife Pharmaceuticals (PTLF), the current Total Equity is $-1.97 Mil as of Feb. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Petlife Pharmaceuticals Business Description

Address 38 West Main Street, 6th Floor, Hancock, MD, USA, 21750
Petlife Pharmaceuticals Inc specializes in the research, development, sales, and support of advanced drugs and nutraceuticals for pet cancer and autoimmune related diseases such as arthritis. It develops potentiated veterinary cancer medications and nutraceuticals, under its tradename Vitalzul based on Escozine formula. The Vitalzul is a polarized, bioactive peptide extracted from the Blue Caribbean Scorpion (Rhopularus Princeps), which contains amino acids, proteins, and minerals.